Galenica: Nine-month sales rise 5.7% as pharmacies drive growth
In short
Galenica’s sales rose 5.7% to CHF 3’172.0 million in January–September 2026. Pharmacy sales increased 6.2%, while Products & Brands declined 7.2%. Galexis completed its ERP changeover in September, after temporary assortment restrictions slowed third-quarter wholesale growth. Galenica maintained its 2026 outlook.
What it means for suppliers
- For prescription-medicine suppliers, demand remains high for GLP-1 weight-loss treatments and medicines for rheumatic diseases.
- Consumer-health suppliers can benchmark sales against Swiss over-the-counter health market growth of 0.3%; Verfora product market sales fell 2.4%.
- For wholesale sales planning, Galenica expects growth to accelerate in the fourth quarter following the completed ERP changeover.
Key facts
| Retailer | Galenica |
|---|---|
| Announced | |
| Categories | Prescription medicines, Over-the-counter health products |
| Effective from | January–September 2026 |
| Source | galenica.com |
Not listed at Galenica yet?
Tell us what you sell. We will tell you how listing works and whether now is a good moment.